Archives202520242023202220212020201920182017201620152014201320122011 March 01, 2016Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Read More February 23, 2016Result of GM Read More February 15, 2016First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More February 15, 2016First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More February 05, 2016Placing and Subscription Raises £8.3 million Read More February 05, 2016Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016 Read More December 15, 2015Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting Read More December 07, 2015Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients Read More November 04, 2015Lupuzor™ Phase III Pivotal Trial Update Read More October 23, 2015Board Change Read More September 30, 2015Tim McCarthy Appointed as Non-executive Chairman Read More September 30, 2015Interim Results Announcement for the six months ended 30 June 2015 Read More 1…1718192021…23
March 01, 2016Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Read More
February 05, 2016Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016 Read More
December 15, 2015Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting Read More
